PMEF
IPSC icon

Point72 Middle East FZE’s Century Therapeutics IPSC Stock Holding History

Point72 Middle East FZE’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,744
Closed -$8.95K – 1899
2022
Q4 		$8.95K Buy
+1,744
New +$16.5K ﹤0.01% 1739

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Middle East FZE's IPSC Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Century Therapeutics (IPSC) in Q1 2023, closing a stake of 1,744 shares — an estimated $8.95K sold.

Point72 Middle East FZE first reported a position in IPSC in Q4 2022 and held it in 1 quarter. The position peaked at $8.95K in Q4 2022. 63 funds tracked by Wall St. Rank hold IPSC as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Century Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 1,744 Century Therapeutics shares in Q1 2023, an estimated $8.95K.
  • Point72 Middle East FZE first reported a position in Century Therapeutics in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Century Therapeutics position peaked at $8.95K in Q4 2022.
  • 63 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.